US Stock Market Movement: Iovance surged on October 27 due to sarcoma data, melanoma data, and TIL therapy

Iovance October 27 Surge Analysis

Keywords: Sarcoma data, melanoma data, TIL therapy

1. On October 26, the company released pilot study data on lifileucel for the treatment of metastatic undifferentiated pleomorphic sarcoma and de-differentiated liposarcoma: among the first 8 evaluable patients, a confirmed objective response rate was 50%, with 4 cases of partial response still ongoing as of the data cutoff date, the longest lasting up to 46 weeks; these results were presented as an oral report at the ESMO 2026 Congress.

2. On October 23, the company released the final phase II analysis of lifileucel in combination with pembrolizumab for first-line advanced melanoma: among 24 patients, a confirmed objective response rate of 62.5% and a complete response rate of 29.2% were observed; at a median follow-up of 50.9 months, median overall survival had not yet been reached. The company stated that these results support the ongoing phase III TILVANCE-301 trial.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)